《港樓》錦上路柏瓏再沽7夥 單日套現6,520萬
信置(00083.HK)、中海外(00688.HK)、嘉華國際(00173.HK)與港鐵(00066.HK)合作發展,位於錦上路站的柏瓏,昨日(21日)再沽7夥,柏瓏I及柏瓏II分別售出3夥及4夥。當中,5夥爲兩房單位,2夥爲三房單位,單日套現逾6,520萬元。
7夥成交單位當中,最高成交價單位爲柏瓏II的8座8樓A2單位,三房一套連儲物房連工作間,實用面積831平方尺,成交價1,279.71萬元,尺價15,400元。最高成交尺價單位則爲柏瓏I 的5座9樓A2單位,兩房間隔,實用面積479平方尺,成交價820.71萬元,尺價17,134元。
項目以現樓形式推售三週已沽出115夥,套現逾10億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.